Showing 15 posts of 19 posts found.


Teva denies wrongdoing in Cephalon pay-to-delay deal hearing

March 14, 2018
Research and Development, Sales and Marketing Cephalon, Pay to delay, Provogil, Teva, pay-to-delay, pharma

Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its …


Mylan pays $96.5 million to settle pay-for-delay case

February 7, 2017
Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust

Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …

Teva settles generic ‘pay-to-delay’ case for $1.2 billion

May 29, 2015
Sales and Marketing Cephalon, FTC, Teva, modafinil, provigil

Teva Pharmaceuticals has agreed to a $1.2 billion settlement for paying generic drug makers to delay challenging the patent for …

Teva image

Teva faces $512m fine in generic Provigil row

April 22, 2015
Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil

Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …

Pfizer picture

Pfizer recalls oral contraceptive for packaging errors

February 2, 2012
Manufacturing and Production Akrimax, Bedford, Cephalon, Lo/Ovral-28, Pfizer, Teva

Pfizer has been forced to recall a large volume of oral contraceptive packs distributed in the US market because a …


Teva’s Cephalon acquisition could be delayed

June 15, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Cephalon, Teva

The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month. …


Cephalon accepts Teva’s $6.8 billion white knight bid

May 3, 2011
Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …


Valeant makes $5.7 billion hostile bid for Cephalon

March 31, 2011
Research and Development, Sales and Marketing Cephalon, Valeant

Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …

Cephalon buys Gemin X for $225 million

March 24, 2011
Research and Development Cephalon, lung cancer

Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …

Allergan marketing breaches discredited industry

March 22, 2011
Medical Communications Allergan, Cephalon, PMCPA

Allergan, the manufacturer of Botox, has been censured for several breaches of the ABPI Code of Practice. The PMCPA watchdog …

ABPI Code of Practice

Cephalon in trouble over party spirit

February 11, 2011
Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation

Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …

Cephalon’s Paul Harmon joins IPHA board

January 10, 2011
Sales and Marketing Cephalon, IPHA, Paul Harmon, appointment, sales and marketing

Cephalon’s Paul Harmon has been elected to the prescription medicines division strategy board of Irish pharma association IPHA, a role …

Cephalon chairman takes leave of absence

September 2, 2010
Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing

Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …

Cephalon completes acquisition of generics firm Mepha

April 16, 2010
Sales and Marketing Cephalon, generics

Specialist pharmaceutical company Cephalon has completed the $615.4 million acquisition of Mepha. Based in Switzerland, Mepha specialises in using reformulation …

Cephalon to develop new class of cancer drug

March 19, 2010
Research and Development CRT, Cancer, Cancer Research UK, Cephalon

Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class …

Latest content